Who
Amrit Ray
Director
Company insider
Files Form 4 as: Director, Fortrea Holdings; Director, Ultragenyx Pharmaceutical.
In numbers
- Trades disclosed
- 27
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 19 Apr 2022
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Code M | —38,817 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | FTRE Fortrea Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —38,817 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | FTRE Fortrea Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —12,852 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | FTRE Fortrea Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —38,817 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | FTRE Fortrea Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —12,852 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Code M | —38,817 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —7,751 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —14,058 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —14,058 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —7,751 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | FTRE Fortrea Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —38,817 at $0.00 | filing |
| 15 May 2025filed 19 May 2025 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —10,787 at $0.00 | filing |
| 15 May 2025filed 19 May 2025 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —5,740 at $0.00 | filing |
| 14 May 2025filed 16 May 2025 | FTRE Fortrea Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —7,282 at $0.00 | filing |
| 14 May 2025filed 16 May 2025 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Code M | —7,282 at $0.00 | filing |
| 18 Jul 2024filed 19 Jul 2024 | FTRE Fortrea Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —6,354 at $0.00 | filing |
| 18 Jul 2024filed 19 Jul 2024 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Code M | —6,354 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —9,900 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —5,345 at $0.00 | filing |
| 14 May 2024filed 16 May 2024 | FTRE Fortrea Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —7,282 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.